8月26日，康臣药业（01681）发布2026年中期业绩，公司收入为17.85亿元，同比增加约13.8%。公司归母净利润为5.95亿元，同比增加约19.5%。每股基本及摊薄盈利分别约为0.71元及0.7元，分别同比增加约20.3%及20.7%。 财务回顾方面，销售收入主要来自于肾科药物系列产品，销售同比增长约18.1%。其他系列如妇儿药物和肝胆药物的销售分别增长约9.1%和233.7%，但医用...
Source Link8月26日，康臣药业（01681）发布2026年中期业绩，公司收入为17.85亿元，同比增加约13.8%。公司归母净利润为5.95亿元，同比增加约19.5%。每股基本及摊薄盈利分别约为0.71元及0.7元，分别同比增加约20.3%及20.7%。 财务回顾方面，销售收入主要来自于肾科药物系列产品，销售同比增长约18.1%。其他系列如妇儿药物和肝胆药物的销售分别增长约9.1%和233.7%，但医用...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.